Arvinas (ARVN) FDA catalyst dates

FreeBioList tracks 6 upcoming catalysts for Arvinas (ARVN, listed on Nasdaq). They cover 5 programmes: ARV-102 (Parkinson’s disease (LRRK2 degrader) — biomarker data), ARV-806 (KRAS G12D-mutant solid tumours (degrader)), ARV-393 (Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader); B- and T-cell lymphomas (BCL6 degrader)) and ARV-027 (Kennedy’s disease (polyQ-AR degrader)), and 1 more.

First on the list: the Phase 1 readout for ARV-102 (Parkinson’s disease (LRRK2 degrader) — biomarker data), guided by the company to Oct 2026. The furthest-out event tracked is Mid 2027. By stage, the upcoming rows are 6 Phase 1 readouts.

All 6 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Arvinas ARVN · Nasdaq	ARV-102	Parkinson’s disease (LRRK2 degrader) — biomarker data	Oct 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "additional biomarker data from the Phase 1 clinical trial ... at the International Congress on Parkinson’s Disease." Conference-dated catalyst. Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026
Arvinas ARVN · Nasdaq	ARV-806	KRAS G12D-mutant solid tumours (degrader)	H2 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides Arvinas will "share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026
Arvinas ARVN · Nasdaq	ARV-393	Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader)	H2 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides sharing "data from early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026
Arvinas ARVN · Nasdaq	ARV-027	Kennedy’s disease (polyQ-AR degrader)	H1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides sharing "initial data evaluating androgen receptor (AR)-degradation in muscle." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026
Arvinas ARVN · Nasdaq	ARV-393	B- and T-cell lymphomas (BCL6 degrader)	Mid 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "additional monotherapy data from the ongoing Phase 1 dose escalation trial in B- and T-cell lymphomas." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026
Arvinas ARVN · Nasdaq	ARV-393 + glofitamab	Diffuse large B-cell lymphoma	Mid 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 12 Sep 2026

Company ▾

Drug ▾

Effect / indication

Next catalyst ▾

Phase / type ▾

Status ▾

Source

Options

Arvinas ARVN · Nasdaq

ARV-102

Parkinson’s disease (LRRK2 degrader) — biomarker data

Oct 2026
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Arvinas ARVN · Nasdaq

ARV-806

KRAS G12D-mutant solid tumours (degrader)

H2 2026
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Arvinas ARVN · Nasdaq

ARV-393

Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader)

H2 2026
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Arvinas ARVN · Nasdaq

ARV-027

Kennedy’s disease (polyQ-AR degrader)

H1 2027
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Arvinas ARVN · Nasdaq

ARV-393

B- and T-cell lymphomas (BCL6 degrader)

Mid 2027
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Arvinas ARVN · Nasdaq

ARV-393 + glofitamab

Diffuse large B-cell lymphoma

Mid 2027
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Companies working on related conditions

Verastem Oncology (VSTM)KRAS G12D-mutant solid tumours; Recurrent low-grade serous ovarian cancer
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
Erasca (ERAS)KRAS-mutant solid tumours (pan-KRAS inhibitor); RAS-mutant solid tumours (pan-RAS inhibitor); RAS-mutant colorectal cancer
Sana Biotechnology (SANA)Non-Hodgkin lymphoma (in vivo CAR-T)
Aktis Oncology (AKTS)Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical); Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)

Also due in Q4 2026

Xencor (XNCR)Phase 1 readout for XmAb819, Oct 2026
Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026
MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026
MacroGenics (MGNX)Phase 1 readout for MGC026, Oct 2026
Neumora Therapeutics (NMRA)Phase 1 readout for NMRA-511, Q4 2026
Kyverna Therapeutics (KYTX)Phase 1 readout for Miv-cel (mivotacel), Q4 2026